LNTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Lantheus Holdings Inc (LNTH) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has a promising radiopharmaceutical pipeline and positive analyst sentiment, the recent financial performance shows significant declines in net income and EPS, and insider/hedge fund selling trends are concerning. Additionally, technical indicators suggest the stock is currently overbought, and there are no strong trading signals from Intellectia Proprietary Trading Signals to support an immediate buy decision.
The stock's MACD is positive at 0.682, indicating bullish momentum, but it is contracting. RSI is at 84.903, signaling the stock is overbought. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading close to its resistance levels (R1: 78.929). The stock has a 40% chance to rise 4.86% in the next day but a higher probability of declining in the next week (-1.47%) and month (-18.15%).
Analysts maintain positive ratings with increased price targets, indicating confidence in the company's long-term growth potential.
The company completed acquisitions of Neuraceq and OCTEVY, which could enhance its product portfolio.
Lantheus's products impacted 7 million patients in 2025, showcasing its market presence.
Insider and hedge fund selling has increased significantly, with insider selling up 5211.12% and hedge fund selling up 2127.26%.
Financial performance in Q4 2025 showed a sharp decline in net income (-558.76% YoY) and EPS (-576.47% YoY).
The stock is overbought based on RSI, suggesting limited immediate upside potential.
In Q4 2025, revenue increased by 4.01% YoY to $406.8 million, but net income dropped by -558.76% YoY to $54.09 million, and EPS fell by -576.47% YoY to $0.81. Gross margin also declined by -6.83% YoY to 59.21%.
Analysts are generally positive on LNTH, with recent upgrades and price target increases. The average price target is around $75-$82, reflecting moderate upside from the current price. Analysts cite the company's radiopharmaceutical pipeline and potential reimbursement resolution in 2026 as key growth drivers.
